Intensity Therapeutics, Inc.
INTS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $147 | $0 | $0 |
| Gross Profit | $0 | -$147 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10,496 | $4,786 | $5,132 | $5,856 |
| G&A Expenses | $6,089 | $3,533 | $2,418 | $2,140 |
| SG&A Expenses | $6,089 | $3,386 | $2,418 | $2,140 |
| Sales & Mktg Exp. | $0 | -$147 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $17 |
| Operating Expenses | $16,585 | $8,172 | $7,550 | $8,014 |
| Operating Income | -$16,585 | -$8,319 | -$7,550 | -$8,014 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $317 | -$2,219 | -$32 | $119 |
| Pre-Tax Income | -$16,268 | -$10,538 | -$7,582 | -$7,895 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16,268 | -$10,538 | -$7,582 | -$7,896 |
| % Margin | – | – | – | – |
| EPS | -1.17 | -0.87 | -0.58 | -0.6 |
| % Growth | -34.5% | -50% | 3.3% | – |
| EPS Diluted | -1.17 | -0.87 | -0.58 | -0.6 |
| Weighted Avg Shares Out | 13,907 | 13,709 | 13,099 | 13,099 |
| Weighted Avg Shares Out Dil | 13,907 | 13,709 | 13,099 | 13,099 |
| Supplemental Information | – | – | – | – |
| Interest Income | $314 | $324 | $2 | $3 |
| Interest Expense | $0 | $305 | $82 | $17 |
| Depreciation & Amortization | $0 | $147 | $0 | $0 |
| EBITDA | -$16,268 | -$10,086 | -$7,500 | -$7,878 |
| % Margin | – | – | – | – |